1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882


Delayed London Stock Exchange  -  05/25 11:35:24 am EDT
1775.00 GBX   -0.39%
05/25Nestlé Said To Have Explored Possible Purchase Of GSK's Consumer Health Unit
05/24TRANSCRIPT : GSK plc Presents at UBS Global Healthcare Conference, May-24-2022 09:15 AM
05/24European executives' confidence plunges on Ukraine crisis - survey
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Shareholder Terry Smith labels Unilever's GSK bid "near death experience"

01/20/2022 | 11:04am EDT
A GSK logo is seen at the GSK research centre in Stevenage

(Reuters) - Influential British fund manager Terry Smith attacked Unilever's failed 50 billion pound ($68.2 billion) bid for GSK's Consumer Health assets as a "near death experience" and urged Unilever management to focus on strengthening performance.

In a letter to investors of his Fundsmith vehicle, now the 13th biggest Unilever shareholder, Smith criticized Unilever for failing to openly communicate the benefits of the deal and its "penchant for corporate gobbledegook as substitute for effective action."

"It seems to us that Unilever management's response to its poor performance has been to utter meaningless platitudes to which it has now attempted to add major M&A activity. What could possibly go wrong?," said the letter, signed by Smith and head of research, Julian Robins.

Unilever did not immediately respond to a request for comment.

Late on Wednesday, Unilever effectively abandoned its offer for GlaxoSmithKline's Consumer Health unit, after the deal was widely panned by the market and analysts.

GSK had said the bid undervalued the business and that it would go ahead with its plan to spin it off instead.

"We are pleased that the Unilever management listened and has seemingly ended the attempt to acquire GSK Consumer by refusing to up its bid for a fourth time," the letter said, describing its critique as a post-mortem into a "near death experience" in the form of the failed approach.

Smith's "near death experience" phrase echoed comments made by Unilever's previous CEO Paul Polman when describing his successful fight against a hostile takeover bid by Kraft Heinz in 2017.

Having rejected the bid, GSK's consumer business would face its own reckoning when it is listed as a separate company later this year, the Fundsmith letter added.

This isn't Smith's first recent attack on Unilever.

Last week, he criticised Unilever for being "obsessed" with sustainability at the expense of performance, after the stock featured among its equity fund's bottom-5 performers in 2021.

($1 = 0.7332 pounds)

(Reporting by Siddharth Cavale in Bengaluru; Editing by Keith Weir)

By Siddharth Cavale

© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC -0.39% 1775 Delayed Quote.10.48%
POLMAN S.A. -0.29% 0.349 End-of-day quote.-30.20%
THE KRAFT HEINZ COMPANY 0.68% 39.88 Delayed Quote.11.09%
UNILEVER PLC -1.26% 3496.5 Delayed Quote.-11.47%
05/25Nestlé Said To Have Explored Possible Purchase Of GSK's Consumer Health Unit
05/24TRANSCRIPT : GSK plc Presents at UBS Global Healthcare Conference, May-24-2022 09:15 AM
05/24European executives' confidence plunges on Ukraine crisis - survey
05/20Deutsche Bank Keeps GSK At Hold, Boosts PT
05/19GLAXOSMITHKLINE : Deutsche Bank remains Neutral
05/19GLAXOSMITHKLINE PLC : Ex-dividend day for interim dividend
05/18S&P Maintains GSK's Ratings, Stable Outlook on Expected Post-Demerger Recovery
05/17FTSE 100 lags European peers on strong pound
05/17GlaxoSmithKline Pharmaceuticals Sees Surge in Fiscal Q4 Consolidated Net Profit
05/16Glaxosmithkline Confirms It Has Changed Its Name To GSK PLC
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Sales 2022 36 527 M 45 865 M 45 865 M
Net income 2022 5 289 M 6 641 M 6 641 M
Net Debt 2022 17 655 M 22 168 M 22 168 M
P/E ratio 2022 16,7x
Yield 2022 2,96%
Capitalization 89 836 M 113 B 113 B
EV / Sales 2022 2,94x
EV / Sales 2023 2,79x
Nbr of Employees 90 096
Free-Float 93,6%
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 1 775,00 GBX
Average target price 1 865,77 GBX
Spread / Average Target 5,11%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Hal V. Barron Executive Director & Chief Scientific Officer
Jon Ellis VP & Head-Technology Business Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON5.00%477 336
PFIZER, INC.-9.04%299 678
ROCHE HOLDING AG-12.57%281 309
ABBVIE INC.12.23%263 494